STAT reports Lilly offered retatrutide to one person under compassionate use
The unapproved triple agonist has drawn expanded-access requests from patients who cannot wait for a filing, but Lilly has cleared just one.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 23 03:00 ETSource: STAT
The wire
- 01STAT reports that Eli Lilly has made its investigational triple agonist retatrutide available to a single individual through a compassionate use, or expanded access, pathway.
- 02Clinicians and patients asking about pre-approval access to retatrutide now have a data point on how narrowly Lilly is granting it.
- 03Details on the patient, indication and Lilly's criteria for further expanded access requests are not laid out in the headline reporting.
From the source
Read at statnews.comLilly’s retatrutide has been offered to a single person via ‘compassionate use’ program